Form 4: Allakos President Adam Tomasi Disposes of Shares and Options in Merger with Concentra Biosciences

Allakos President Adam Tomasi disposed of shares and stock options following the merger agreement with Concentra Biosciences, receiving $0.33 per share.

Summary

• Adam Tomasi, President of Allakos Inc., filed a Form 4 detailing changes in beneficial ownership.
• The filing reports transactions occurring on May 15, 2025, related to the merger agreement between Allakos Inc., Concentra Biosciences, LLC, and Concentra Merger Sub III, Inc.
• Tomasi disposed of 512,630 shares of common stock in exchange for $0.33 per share in cash.
• He also disposed of 20,790 shares held indirectly through the Tomasi Living Trust.
• Multiple stock options were cancelled without consideration as part of the merger agreement, including options to buy 486,400 shares at $0.69, 145,011 shares at $4.01, 88,036 shares at $4.31, 125,000 shares at $35.28, 300,471 shares at $7.2, and 1,200,000 shares at $1.25.
• Following these transactions, Tomasi's direct ownership of common stock is reported as 0 shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the disposal of shares at a low price and the cancellation of stock options, indicating a loss of value for the reporting person. The merger itself may not be viewed positively from the perspective of Allakos shareholders.

Negatives

• The cancellation of stock options represents a loss of potential future value for Adam Tomasi.
• The sale of shares at $0.33 may be considered a negative outcome if the initial investment was higher.

Future Outlook

The future outlook for Adam Tomasi's holdings in Allakos is limited, given the completion of the merger with Concentra Biosciences and the disposal/cancellation of his shares and options.

Industry Context

This announcement reflects the completion of a merger transaction, which is a common occurrence in the biotechnology industry as companies seek to consolidate resources, technologies, or pipelines. The disposal of shares and cancellation of options by a company president is a typical consequence of such a merger.

Comparison to Industry Standards

• Mergers and acquisitions in the biotech industry often result in changes in executive holdings, similar to what is seen here with Adam Tomasi.
• The valuation of $0.33 per share suggests a distressed sale, which is not uncommon for companies facing financial difficulties or clinical trial setbacks, similar to what has been observed with other struggling biotech firms.
• Comparable companies that have undergone similar merger scenarios include [hypothetical company A] and [hypothetical company B], where executives also had to dispose of their holdings as part of the transaction.

Stakeholder Impact

• Shareholders of Allakos likely experienced a significant loss in value due to the low merger price.
• Employees of Allakos may face uncertainty regarding their future employment with the merged entity.

Key Dates

Keywords

Form 4, Allakos Inc., Adam Tomasi, Concentra Biosciences, Merger, Stock Options, Beneficial Ownership, Disposition of Shares